Llwytho...
Incidence of Adverse Effects and Discontinuation Rate between Patients Receiving 250 Micrograms and 500 Micrograms of Roflumilast: A Comparative Study
BACKGROUND: Roflumilast is the only approved oral phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease (COPD) in patients with chronic bronchitis and a history of frequent exacerbations. The purpose of this study was to examine the incidence of adverse effe...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Tuberc Respir Dis (Seoul) |
|---|---|
| Prif Awduron: | , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2018
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6148098/ https://ncbi.nlm.nih.gov/pubmed/29926552 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4046/trd.2018.0015 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|